Strategic Asset Divestment GSK recently sold a biopharmaceutical manufacturing facility to Samsung Biologics for $280 million, indicating an openness to strategic partnerships and asset divestments that could open avenues for innovative supply chain collaborations or licensing opportunities.

Research & Development Focus GSK is actively developing advanced therapies such as myeloid cell engagers and advancing its liver pipeline, presenting opportunities to provide specialized technology solutions, research tools, or partnerships in biotech and pharmaceutical R&D.

Global Expansion Efforts With recent collaborations and facility transactions in the U.S. and across Asia, GSK is pursuing targeted growth through international alliances, making it a potential partner for global supply chain optimization, clinical trial services, or market expansion support.

Commitment to Social Responsibility The launch of the GSK Scholars Programme to support underprivileged MBBS students demonstrates their focus on community engagement, which could translate into opportunities for CSR-focused sponsorships, educational partnerships, or health initiatives.

Operational and Sustainability Projects GSK's involvement with demolition services and organizational engagement awards suggest active investments in operational efficiency and sustainability, signaling potential needs for environmental consulting, waste management, and sustainability technology solutions.